Caris Life Sciences (NASDAQ:CAI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Caris Life Sciences (NASDAQ:CAI) from a hold rating to a buy rating in a report released on Saturday.

A number of other research firms also recently commented on CAI. Evercore set a $38.00 price objective on shares of Caris Life Sciences in a research note on Monday, January 5th. Canaccord Genuity Group boosted their target price on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Robert W. Baird lifted their price target on Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th. Finally, BTIG Research lowered their price objective on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $33.50.

Caris Life Sciences Stock Up 2.2%

Shares of CAI opened at $19.00 on Friday. The firm has a market cap of $5.37 billion and a price-to-earnings ratio of -105.56. The company has a debt-to-equity ratio of 0.66, a quick ratio of 7.35 and a current ratio of 7.85. The firm has a 50 day simple moving average of $23.37. Caris Life Sciences has a 52-week low of $17.15 and a 52-week high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million for the quarter, compared to analyst estimates of $281.00 million. The firm’s quarterly revenue was up 125.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.73) EPS.

Insider Buying and Selling at Caris Life Sciences

In related news, insider Luke Thomas Power sold 62,250 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the sale, the insider owned 99,571 shares of the company’s stock, valued at $2,646,597.18. This represents a 38.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hedge Funds Weigh In On Caris Life Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Global Retirement Partners LLC grew its holdings in shares of Caris Life Sciences by 99,900.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after purchasing an additional 999 shares during the last quarter. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences in the 4th quarter worth approximately $31,000. MetLife Investment Management LLC boosted its position in Caris Life Sciences by 84.0% during the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after purchasing an additional 755 shares during the period. Aster Capital Management DIFC Ltd bought a new position in Caris Life Sciences during the 4th quarter worth $67,000. Finally, Federated Hermes Inc. bought a new position in Caris Life Sciences during the 4th quarter worth $81,000.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.